HR8933

1) On May 20, 2026, Rep. LaHood (R-IL) introduced HR8933, the Dietary Supplements Access Act. The bill was referred to the House Ways and Means Committee, the tax-writing committee. It has three cosponsors (one Democrat, two Republicans) and an identical companion bill (S4587) in the Senate referred to the Finance Committee. The bill is early-stage — it has taken no further legislative action beyond introduction and referral. 2) The bill operates through tax code amendments — it does NOT authorize or appropriate any government spending. It amends Sections 223 (HSAs), 220 (Archer MSAs), and 106 (FSAs/HRAs) of the Internal Revenue Code to include dietary supplements (defined per FDA 21 U.S.C. 321(ff), explicitly excluding energy drinks, soft drinks, and sodas) as qualified medical expenses up to $500/year ($250 MFS). The effective date is retroactive to December 31, 2025. This means 2026 tax-year contributions can already be used for supplements if the bill passes. The budgetary impact is reduced tax revenue (estimated small because HSA/FSA dollars are pre-tax either way — the bill just expands what they can buy). 3) This bill is a modest positive for supplement manufacturers but unlikely to move share prices measurably. Pure-play publicly traded supplement companies include Nu Skin Enterprises ($NUS), Herbalife ($HLF), and USANA Health Sciences ($USNA). The mechanism is consumer behavior change — supplements become 22-37% cheaper for the ~70 million Americans with HSAs (2025 figure) and the much larger FSA user base. However, HSA/FSA account balances are not new money — they are pre-tax dollars already set aside for medical expenses. This bill lets existing dollars buy supplements rather than other qualified expenses (co-pays, prescriptions, dental). The net new demand for supplements is likely modest. The bill explicitly excludes energy drinks, which protects traditional supplement manufacturers from competition from beverage companies ($CELH, $KDP). 4) No REAL MARKET DATA available on supplement stock performance. The broader supplement industry is ~$55B in the US (2025) with ~3% annual growth. This bill could add 0.5-1% to industry revenue in the first year, concentrated in the HSA/FSA channel. 5) Timeline: This is early-stage legislation with a narrow tax benefit. Passage probability rises if it gets included in a tax extenders package (likely in 2026-2027) but faces long odds as a stand-alone bill given the crowded 119th Congress calendar. The House Ways and Means Committee markup is the next milestone. If no markup by Sept 2026, the bill likely dies. Companion bill in Senate Finance provides a parallel path.